Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department

被引:17
|
作者
Peyrony, Olivier [1 ]
Tieghem, Yoann [1 ]
Franchitti, Jessica [1 ]
Ellouze, Sami [1 ]
Morra, Ivonne [1 ]
Madelaine-Chambrin, Isabelle [2 ]
Flicoteaux, Remi [3 ]
Baroudjian, Barouyr [4 ,5 ]
Azoulay, Elie [6 ,7 ]
Chevret, Sylvie [3 ,7 ]
Fontaine, Jean-Paul [1 ]
机构
[1] Hop St Louis, Emergency Dept, F-75475 Paris, France
[2] Hop St Louis, Pharm Dept, Paris, France
[3] Hop St Louis, Biostat & Med Informat Dept, Paris, France
[4] Hop St Louis, Dermatol Dept, Paris, France
[5] Hop St Louis, Partage Experience Autour Tox Immunotherapies Onc, Paris, France
[6] Hop St Louis, Intens Care Unit, Paris, France
[7] Univ Paris Diderot, Paris, France
关键词
MANAGEMENT;
D O I
10.1136/emermed-2018-208091
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives We sought to estimate the prevalence of patients with cancer presenting to the emergency department (ED) who are undergoing treatment with immune checkpoint blockade (ICB) therapy; report their chief complaints; describe and estimate the prevalence of immune-related adverse events (IRAEs). Methods Four abstractors reviewed the medical records of patients with cancer treated with ICB who presented to an ED in Paris, France between January 2012 and June 2017. Chief complaints, underlying malignancy and ICB characteristics, and the final diagnoses according to the emergency physician were recorded. Abstractors noted if an emergency physician identified that a patient was receiving an ICB and if the emergency physician considered the possibility of an IRAE. The gold standard as to whether an IRAE was the cause was the patients' referring oncologist's opinion that the ED symptoms were attributed to ICB and IRAE according to post-ED medical records. Descriptive statistics were reported. Results Among the 409 patients treated with ICB at our institution, 139 presented to the ED. Chief complaints were fatigue (25.2%), fever (23%), vomiting (13.7%), diarrhoea (13.7%), dyspnoea (12.2%), abdominal pain (11.5%), confusion (8.6%) and headache (7.9%). Symptoms were due to IRAEs in 20 (14.4%) cases. The most frequent IRAEs were colitis (40%), endocrine toxicity (30%), hepatitis (25%) and pulmonary toxicity (5%). Patients with IRAEs compared with those without them more frequently had melanoma; had received more distinct courses of ICB treatment, an increased number of ICB medications and ICB cycles; and had a shorter time course since the last infusion of ICB. Emergency physicians considered the possibility of an IRAE in 24 (17.3%) of cases and diagnosed IRAE in 10 (50%) of those with later confirmed IRAE. IRAE was more likely to be missed when the referring oncologist was not contacted or when the patient had respiratory symptoms, fatigue or fever. Conclusions ICB exposes patients to potentially severe IRAEs. Emergency physicians must identify patients treated with ICB and consider their toxicity when patients present to the ED with symptoms compatible with IRAEs.
引用
收藏
页码:306 / 309
页数:4
相关论文
共 50 条
  • [41] Incidence of Hyperthyroidism Among Patients Presenting to the Emergency Department With Atrial Fibrillation
    Katz, T.
    Vanga, S.
    Hoon, C. J.
    Jasani, N.
    Rahman, E.
    ANNALS OF EMERGENCY MEDICINE, 2013, 62 (04) : S37 - S37
  • [42] Prevalence of pulmonary embolism among patients presenting to emergency department for hemoptysis
    Vanni, S.
    Gori, L.
    Coppa, A.
    Nazerian, P.
    Giannasi, G.
    Ruggiano, G.
    De Curtis, E.
    Baldini, A.
    Pepe, G.
    Magazzini, S.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1900 - 1900
  • [43] Analysis of readmissions to the emergency department among patients presenting with abdominal pain
    Kacprzyk, Artur
    Stefura, Tomasz
    Chlopas, Katarzyna
    Trzeciak, Kaja
    Zalustowicz, Aleksandra
    Rubinkiewicz, Mateusz
    Pedziwiatr, Michal
    Rembiasz, Kazimierz
    Major, Piotr
    BMC EMERGENCY MEDICINE, 2020, 20 (01)
  • [44] A review of immune checkpoint blockade in breast cancer
    Pellegrino, Benedetta
    Tommasi, Chiara
    Cursio, Olga Elisabetta
    Musolino, Antonino
    Migliori, Edoardo
    De Silva, Pushpamali
    Senevirathne, Thilini Hemali
    Schena, Marina
    Scartozzi, Mario
    Farci, Daniele
    Willard-Gallo, Karen
    Solinas, Cinzia
    SEMINARS IN ONCOLOGY, 2021, 48 (03) : 208 - 225
  • [45] Gastric Cancer in the Era of Immune Checkpoint Blockade
    Figueroa-Protti, Lucia
    Soto-Molinari, Rebeca
    Calderon-Osorno, Melany
    Mora, Javier
    Alpizar-Alpizar, Warner
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [46] Immune Checkpoint Blockade in Breast Cancer Therapy
    Bu, Xia
    Yao, Yihui
    Li, Xiaoyu
    TRANSLATIONAL RESEARCH IN BREAST CANCER: BIOMARKER DIAGNOSIS, TARGETED THERAPIES AND APPROACHES TO PRECISION MEDICINE, 2017, 1026 : 383 - 402
  • [47] Immune checkpoint blockade therapy in cancer and beyond
    Minato, Nagahiro
    CYTOKINE, 2017, 100 : 23 - 23
  • [48] Immune Checkpoint Blockade in Metastatic Urothelial Cancer
    Balar, Arjun Vasant
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2109 - +
  • [49] Training the microbiota to increase immune checkpoint blockade and to reduce toxicity
    Rescigno, Maria
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023,
  • [50] Re: Germline Variants Associated with Toxicity to Immune Checkpoint Blockade
    Jones, James O.
    Mitchell, Thomas J.
    Stewart, Grant D.
    EUROPEAN UROLOGY, 2023, 84 (06) : 597 - 597